A population-based study of retinoblastoma incidence and survival in Argentine children

Authors

  • Florencia Moreno MD,

    Corresponding author
    1. Registro Onco-pediatrico Hospitalario Argentino (ROHA, Hospital-based Pediatric Cancer Registry from Argentina), Instituto Nacional del Cáncer, Buenos Aires, Argentina
    • Correspondence to: Florencia Moreno, Registro Onco-pediatrico Hospitalario Argentino (ROHA, Hospital-based Pediatric Cancer Registry from Argentina), Instituto Nacional del Cáncer, Av Julio A. Roca 781 Piso 11, Buenos Aires C1067 ABC, Argentina.

      E-mail: roha@roha.org.ar

    Search for more papers by this author
  • Banafsheh Sinaki MPH,

    1. Department of Pediatrics, New York Medical College, New York, New York
    Search for more papers by this author
  • Adriana Fandiño MD,

    1. Ophthalmology Service, Hospital JP Garrahan, Buenos Aires, Argentina
    Search for more papers by this author
  • Verónica Dussel MD, MPH,

    1. Registro Onco-pediatrico Hospitalario Argentino (ROHA, Hospital-based Pediatric Cancer Registry from Argentina), Instituto Nacional del Cáncer, Buenos Aires, Argentina
    2. Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina
    3. Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, Massachusetts
    Search for more papers by this author
  • Liliana Orellana PhD,

    1. Instituto de Cálculo, University of Buenos Aires, Buenos Aires, Argentina
    Search for more papers by this author
  • Guillermo Chantada MD, PhD

    1. Hematology-Oncology Service, Hospital JP Garrahan, Buenos Aires, Argentina
    Search for more papers by this author

  • Conflict of Interest: Nothing to report.

Abstract

Background

An increased incidence of retinoblastoma in some developing countries has been reported but no conclusive data are available from population-based studies at national level.

Purpose

To report the incidence and survival of retinoblastoma in Argentina from the National Pediatric Cancer Registry (ROHA) and the influence of socio-economical indicators on outcome.

Procedure

Cases reported to the ROHA (2000–2009) were analyzed. Incidence rates were calculated using National Vital Statistics and survival was estimated. The extended human development index (EHDI) was used as a socio-economical indicator.

Results

With 438 patients reported, an incidence of 5.0 cases per million children 0–14 years old (95% CI 3.5–6.4) was calculated. Median age at diagnosis was significantly higher for children from provinces with lower EHDI; (24 vs. 35 months for unilateral, (P = 0.003) and 9 versus 11.5 months for bilateral retinoblastoma (P = 0.027). The 3-year probability of survival was 0.87 and 0.94 for unilateral and bilateral retinoblastoma, respectively. Residents in provinces with higher EHDI had a better 3-year survival (0.93 vs. 0.77 for lower EHDI, P < 0.0001). Probability of survival was higher for patients treated at tertiary level institutions (P = 0.0015). The combination of low EHDI residence province with no treatment at a tertiary institution was associated with the worst survival outcome. For both, unilateral and bilateral disease, children who died were in average diagnosed at older age.

Conclusions

The incidence of retinoblastoma in Argentina is comparable to that of developed countries. Retinoblastoma is diagnosed later and survival is lower in the less developed areas of the country. Pediatr Blood Cancer 2014;61:1610–1615. © 2014 Wiley Periodicals, Inc.

Ancillary